Trial Profile
A phase III follow-on study investigating 13-valent pneumococcal conjugate vaccine (PCV13) in children previously vaccinated with 4 doses of 7-valent or 13-valent pneumococcal conjugate vaccine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2015
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Pfizer
- 29 Dec 2015 New trial record